Blocking Certain Glutamate Receptors Seen to Ease Huntington’s Advance in Mouse Model of Disease Retrophin, Horizon Donate $3M Each to Rare Disease Institute at Children’s National Emerald Health’s Huntington’s Therapy Candidate EHP-102 Granted FDA Orphan Drug Status Huntington’s Patients’ Skin Cells Transformed Into Nerve Cells That Mimic Disease Symptoms BioNews to Cover 3 Rare Disease Day Events, Including NIH Conference Huntington Chile
